Successful adalimumab treatment of HLA B27 negative heel enthesitis documented with MRI and US

Clinical and Experimental Rheumatology

Volumn 28, Issue 3, 2010, Pages 443-444

  Mancarella, L ^a   Battaglia, M ^a   Addimanda, O ^a   Pelotti, P ^a   Galletti, S ^a   Meliconi, Riccardo ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; HLA B27 ANTIGEN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CLINICAL EXAMINATION; ENTHESITIS; HEEL; HUMAN; IMMUNOTHERAPY; LABORATORY TEST; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; CALCANEUS; ECHOGRAPHY; GENETICS; PATHOLOGY; SPONDYLARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CALCANEUS; HLA-B27 ANTIGEN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SPONDYLARTHRITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957014325     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. D'AGOSTINO MA. OLIVIERI I: Enthesitis. Best Practice & Research Clinical Rheumatology 2006; 20: 473-86.
2. D'AGOSTINO MA, BREBAN M, SAID-NAHAL R, DOUGADOS M: Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 2002; 46: 840-1.
3. OLlVIERI I, SCARANO E, PADULA A, D'ANGELO S, CANTINI F: Switching tumor necrosis factor α inhibitors in HLA-B27-associated severe heel enthesitis. Arthritis Rheum 2007; 57: 1572-4.
4. OLIVIERI I, SCARANO E, GIGLIOTTI P, GIASI V, PADULA A: Successful treatment of juvenile-onset HLA B27 associated severe and refractory heel enthesitis with adalimumab documented by magnetic resonance imaging. Rheumatology (Oxford) 2006; 45: 1315-7.
5. HEUFT-DORENBOSCH L, SPOORENBERG A, VAN TUBERGEN A et al.: Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32.
6. HEALY PJ, HELLIWELL PS: Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-91.
7. GENC H, DUYUR CAKIT B, NACIR B, SARACOGLU M, KACAR M, ERDEM HR: The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 2007; 26: 1104-10.
8. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al:. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
9. SALVARANI C, OLIVIERI I, PIPITONE N et al:. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 2006; 24: 70-8.
10. D'ANGELO S, PADULA A, NIGRO A et al:. Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology. Clin Exp Rheumatol 2008; 26. 1005-11.